Why Is MaxCyte Losing a Longstanding Board Member This Year?

2 min read | December 23, 2024 02:43 AM PST | By Team Kalkine Media

Why Is MaxCyte Losing a Longstanding Board Member This Year? — Image source: Shuutterstock

Achievements Under Mandell’s Tenure

During his time with MaxCyte, Mandell played a significant role in guiding the company through various milestones. Among these was the company’s public listing on both the UK AIM and the US Nasdaq, which marked critical steps in its growth and global presence. He also contributed to the development and launch of MaxCyte's ExPERT™ platform, a leading technology in cell engineering applications.

MaxCyte further expanded its footprint in the biopharmaceutical field by securing 29 Strategic Platform Licenses with companies involved in cell and gene therapy. These collaborations have positioned the company as a key partner in advancing medical innovation. Another notable achievement was MaxCyte’s support in enabling the first FDA-approved CRISPR-edited non-viral cell therapy, underscoring its leadership in cutting-edge therapeutics.

Acknowledgment of Mandell’s Contributions

Richard Douglas, Chairman of MaxCyte's Board, expressed his gratitude for Mandell's contributions, highlighting his influence on the company’s trajectory and role in solidifying its position as a leader in cell engineering. Douglas emphasized that Mandell’s leadership and insights have been integral to MaxCyte’s ability to make a significant impact in the field.

Transition for the Future

As MaxCyte continues to grow and innovate in the cell engineering space, the Board’s transition to nine members reflects a commitment to maintaining strong governance. The company remains focused on advancing its mission and fostering groundbreaking developments in the biotechnology sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.